Kendall Dutchak
A5085929194- Chromatin Remodeling and Cancer
- Ferroptosis and cancer prognosis
- Advanced Breast Cancer Therapies
- Epigenetics and DNA Methylation
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Hippo pathway signaling and YAP/TAZ
- Cancer, Hypoxia, and Metabolism
- Histone Deacetylase Inhibitors Research
- Telomeres, Telomerase, and Senescence
- Cancer Research and Treatments
- Mitochondrial Function and Pathology
- CRISPR and Genetic Engineering
- Cellular Mechanics and Interactions
- RNA Interference and Gene Delivery
- Melanoma and MAPK Pathways
- Plant Surface Properties and Treatments
- Virus-based gene therapy research
- Cancer-related Molecular Pathways
McGill University
2013-2024
Abstract Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including KRAS-mutant non–small cell lung (NSCLC). However, the clinical efficacy of CDK4/6 is limited due to frequent drug resistance their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred inhibitor palbociclib in NSCLC cells. Inhibition BRD4, either by...
Abstract Oncogenic activation of the RTK–RAS–RAF–MEK–ERK pathway occurs in approximately 25% all human cancers, yet activated RAS, BRAF, or MEK expression primary cells leads to a prolonged and predominantly irreversible cell-cycle arrest termed oncogene-induced senescence (OIS). OIS acts as an intrinsic tumor suppressor mechanism, serving barrier progression. Screening library kinases kinase-regulatory proteins we identified MOB3A, Mps-one binder coactivator (MOB) protein family member,...
The ability to express exogenous cDNAs while suppressing endogenous genes via RNAi represents an extremely powerful research tool with the most efficient non-transient approach being accomplished through stable viral vector integration. Unfortunately, since traditional restriction enzyme based methods for constructing such vectors are sequence dependent, their construction is often difficult and not amenable mass production. Here we describe a non-sequence dependent Gateway recombination...
<div>Abstract<p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including <i>KRAS</i>-mutant non–small cell lung (NSCLC). However, the clinical efficacy of CDK4/6 is limited due to frequent drug resistance their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred inhibitor palbociclib in...
<div>Abstract<p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including <i>KRAS</i>-mutant non–small cell lung (NSCLC). However, the clinical efficacy of CDK4/6 is limited due to frequent drug resistance their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred inhibitor palbociclib in...
<p>List of common direct target genes BRD4 in KRAS-mutant NSCLC cells.</p>
<p>List of NSCLC cell lines with corresponding BRD4 mRNA levels and IC50 values for palbociclib.</p>
<p>List of supplementary data and Supplementary Figures 1-9.</p>
<div>Abstract<p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including <i>KRAS</i>-mutant non–small cell lung (NSCLC). However, the clinical efficacy of CDK4/6 is limited due to frequent drug resistance their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred inhibitor palbociclib in...
<p>List of NSCLC cell lines with corresponding BRD4 mRNA levels and IC50 values for palbociclib.</p>
<p>List of top candidates identified from the cDNA screen.</p>
<p>List of genes related to cell cycle that are suppressed by BRD4 inhibition.</p>
<p>List of top candidates identified from the cDNA screen.</p>
<p>List of BRD4 binding regions on gene loci related to cell cycle.</p>
<p>List of genes related to cell cycle that are suppressed by BRD4 inhibition.</p>
<p>List of BRD4 binding regions on gene loci related to cell cycle.</p>
<p>List of top candidates identified from the cDNA screen.</p>
<p>List of NSCLC cell lines with corresponding BRD4 mRNA levels and IC50 values for palbociclib.</p>
<p>List of common direct target genes BRD4 in KRAS-mutant NSCLC cells.</p>
<p>List of genes related to cell cycle that are suppressed by BRD4 inhibition.</p>
<p>List of supplementary data and Supplementary Figures 1-9.</p>
<p>List of genes related to cell cycle that are suppressed by BRD4 inhibition.</p>
<p>List of common direct target genes BRD4 in KRAS-mutant NSCLC cells.</p>
<p>List of NSCLC cell lines with corresponding BRD4 mRNA levels and IC50 values for palbociclib.</p>